ARS Pharmaceuticals, Inc (SPRY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has a cash flow conversion efficiency ratio of -0.381x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.48 Million) by net assets ($114.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SPRY stock market capitalisation for the company's overall valuation and market capitalisation.
ARS Pharmaceuticals, Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how ARS Pharmaceuticals, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ARS Pharmaceuticals, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their cash flow conversion efficiency. Explore SPRY cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IGG Inc
F:I91
|
-0.006x |
|
Focus Hotmelt Co. Ltd. A
SHE:301283
|
N/A |
|
Yunnan Yuntou Ecology and Environment Technology Co Ltd
SHE:002200
|
-0.032x |
|
Norma Group AG NA O.N.
XETRA:NOEJ
|
0.035x |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
-0.128x |
|
Volatus Aerospace Inc
V:FLT
|
-0.152x |
|
Hunan Sokan New Materials Co. Ltd. A
SHG:688157
|
N/A |
|
SNT Motiv Co Ltd
KO:064960
|
0.028x |
Annual Cash Flow Conversion Efficiency for ARS Pharmaceuticals, Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of ARS Pharmaceuticals, Inc from 2018 to 2025. View SPRY stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $114.26 Million | $-170.87 Million | -1.495x | -2934.56% |
| 2024-12-31 | $256.80 Million | $13.55 Million | 0.053x | +120.54% |
| 2023-12-31 | $230.76 Million | $-59.27 Million | -0.257x | -74.87% |
| 2022-12-31 | $272.89 Million | $-40.08 Million | -0.147x | -126.15% |
| 2021-12-31 | $-31.27 Million | $-17.56 Million | 0.562x | +187.00% |
| 2020-12-31 | $-14.05 Million | $9.07 Million | -0.646x | -119.14% |
| 2019-12-31 | $-5.60 Million | $-18.90 Million | 3.373x | +463.71% |
| 2018-12-31 | $18.20 Million | $-16.88 Million | -0.927x | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more